Literature DB >> 26475040

Different target specificities of haptoglobin and hemopexin define a sequential protection system against vascular hemoglobin toxicity.

Jeremy W Deuel1, Florence Vallelian1, Christian A Schaer1, Michele Puglia2, Paul W Buehler3, Dominik J Schaer4.   

Abstract

Free hemoglobin (Hb) triggered vascular damage occurs in many hemolytic diseases, such as sickle cell disease, with an unmet need for specific therapeutic interventions. Based on clinical observations the Hb and heme scavenger proteins haptoglobin (Hp) and hemopexin (Hx) have been characterized as a sequential defense system with Hp as the primary protector and Hx as a backup when all Hp is depleted during more severe intravascular hemolysis. In this study we present a mechanistic rationale for this paradigm based on a combined biochemical and cell biological approach directed at understanding the unique roles of Hp and Hx in Hb detoxification. Using a novel in vitro model of Hb triggered endothelial damage, which recapitulates the well-characterized pathophysiologic sequence of oxyHb(Fe(2+)) transformation to ferric Hb(Fe(3+)), free heme transfer from ferric Hb(Fe(3+)) to lipoprotein and subsequent oxidative reactions in the lipophilic phase. The accumulation of toxic lipid peroxidation products liberated during oxidation reactions ultimately lead to endothelial damage characterized by a specific gene expression pattern with reduced cellular ATP and monolayer disintegration. Quantitative analysis of key chemical and biological parameters allowed us to precisely define the mechanisms and concentrations required for Hp and Hx to prevent this toxicity. In the case of Hp we defined an exponential relationship between Hp availability relative to oxyHb(Fe(2+)) and related protective activity. This exponential relationship demonstrates that large Hp quantities are required to prevent Hb toxicity. In contrast, the linear relationship between Hx concentration and protection defines a highly efficient backup scavenger system during conditions of large excess of free oxyHb(Fe(2+)) that occurs when all Hp is consumed. The diverse protective function of Hp and Hx in this model can be explained by the different target specificities of the two proteins.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endothelial cell; Haptoglobin; Hemoglobin; Hemolysis; Hemopexin; Lipid oxidation; Lipoprotein

Mesh:

Substances:

Year:  2015        PMID: 26475040     DOI: 10.1016/j.freeradbiomed.2015.09.016

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  33 in total

Review 1.  New insights into sickle cell disease: mechanisms and investigational therapies.

Authors:  Gregory J Kato
Journal:  Curr Opin Hematol       Date:  2016-05       Impact factor: 3.284

2.  Determination of extinction coefficients of human hemoglobin in various redox states.

Authors:  Fantao Meng; Abdu I Alayash
Journal:  Anal Biochem       Date:  2017-01-06       Impact factor: 3.365

3.  P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner.

Authors:  Nicolas S Merle; Romain Paule; Juliette Leon; Marie Daugan; Tania Robe-Rybkine; Victoria Poillerat; Carine Torset; Véronique Frémeaux-Bacchi; Jordan D Dimitrov; Lubka T Roumenina
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-08       Impact factor: 11.205

4.  Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles.

Authors:  Nicolas S Merle; Anne Grunenwald; Helena Rajaratnam; Viviane Gnemmi; Marie Frimat; Marie-Lucile Figueres; Samantha Knockaert; Sanah Bouzekri; Dominique Charue; Remi Noe; Tania Robe-Rybkine; Marie Le-Hoang; Nathan Brinkman; Thomas Gentinetta; Monika Edler; Sara Petrillo; Emanuela Tolosano; Sylvia Miescher; Sylvain Le Jeune; Pascal Houillier; Sophie Chauvet; Marion Rabant; Jordan D Dimitrov; Veronique Fremeaux-Bacchi; Olivier P Blanc-Brude; Lubka T Roumenina
Journal:  JCI Insight       Date:  2018-06-21

5.  Haptoglobin Preserves Vascular Nitric Oxide Signaling during Hemolysis.

Authors:  Christian A Schaer; Jeremy W Deuel; Daniela Schildknecht; Leila Mahmoudi; Ines Garcia-Rubio; Catherine Owczarek; Stefan Schauer; Reinhard Kissner; Uddyalok Banerjee; Andre F Palmer; Donat R Spahn; David C Irwin; Florence Vallelian; Paul W Buehler; Dominik J Schaer
Journal:  Am J Respir Crit Care Med       Date:  2016-05-15       Impact factor: 21.405

6.  Haptoglobin administration into the subarachnoid space prevents hemoglobin-induced cerebral vasospasm.

Authors:  Michael Hugelshofer; Raphael M Buzzi; Christian A Schaer; Henning Richter; Kevin Akeret; Vania Anagnostakou; Leila Mahmoudi; Raphael Vaccani; Florence Vallelian; Jeremy W Deuel; Peter W Kronen; Zsolt Kulcsar; Luca Regli; Jin Hyen Baek; Ivan S Pires; Andre F Palmer; Matthias Dennler; Rok Humar; Paul W Buehler; Patrick R Kircher; Emanuela Keller; Dominik J Schaer
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

Review 7.  Deferoxamine therapy reduces brain hemin accumulation after intracerebral hemorrhage in piglets.

Authors:  Shengli Hu; Ya Hua; Richard F Keep; Hua Feng; Guohua Xi
Journal:  Exp Neurol       Date:  2019-05-10       Impact factor: 5.330

8.  Hemopexin increases the neurotoxicity of hemoglobin when haptoglobin is absent.

Authors:  Jing Chen-Roetling; Sheng-Kai Ma; Yang Cao; Aishwarya Shah; Raymond F Regan
Journal:  J Neurochem       Date:  2018-04-03       Impact factor: 5.372

9.  Haptoglobin increases the vulnerability of CD163-expressing neurons to hemoglobin.

Authors:  Jing Chen-Roetling; Raymond F Regan
Journal:  J Neurochem       Date:  2016-07-22       Impact factor: 5.372

10.  Sustained treatment of sickle cell mice with haptoglobin increases HO-1 and H-ferritin expression and decreases iron deposition in the kidney without improvement in kidney function.

Authors:  Patricia A Shi; Erika Choi; Narendranath R Chintagari; Julia Nguyen; Xinhua Guo; Karina Yazdanbakhsh; Narla Mohandas; Abdu I Alayash; Elizabeth A Manci; John D Belcher; Gregory M Vercellotti
Journal:  Br J Haematol       Date:  2016-08-10       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.